Ionizing radiation can reduce stiffness of tumor cell microenvironment

NewsGuard 100/100 Score

Nearly half of all cancer patients receive radiation therapy to curb the growth of malignant cells. But little is known about how ionizing radiation affects the extracellular matrix (ECM), a patchwork of proteins and other biomolecules that surrounds cells and plays a vital role in their shape, movement and signaling functions. One team of researchers from Vanderbilt University aims to unlock how irradiation might alter the mechanical properties of the microenvironment.

The team demonstrated that ionizing radiation can reduce the stiffness of both the ECM of an extracted tumor and an isolated matrix of collagen fibers. Appearing this week in APL Bioengineering's special issue on the "Bioengineering of Cancer," from AIP Publishing, their results pave the way for irradiation to be used to create matrices with tailored properties, and suggest that radiation therapy might have effects beyond disrupting cellular DNA.

"We wanted to know how radiation effects the tissues surrounding cells, particularly how this changes the stiffness of the matrix," said Cynthia Reinhart-King, an author on the paper. "The change in tissue stiffness during tumor growth can be palpable. Stiffness, for example, is what you would look for in breast self-exams."

As cancer cells grow and become increasingly dysfunctional, the network of biomolecules surrounding them are deposited more and begin cross-linking more, leading to a thicker, stiffer matrix. This tougher ECM is vital for the cancer cells to migrate throughout the body, signal to one another, and form tumors. Targeting the ECM's stiffness has become a promising tool in attacking cancer cells.

"Twenty years ago, if you had asked what the primary drivers of cancer were and where the primary focus of the research should be, it would have been largely on genetics, and it still is for personalized medicine," Reinhart-King said.

To date, much of the research on irradiation's effects on the cellular microenvironment has dealt with samples that included cells, obfuscating the irradiation's effect on just the ECM rather than the cell's internal machinery.

Infrared spectroscopy revealed that the radiation does not break down individual fibers of collagen, the long, thin structural proteins that act as the matrix's scaffolding. Instead, it softens the matrix by cutting the bonds between these fibers, relaxing the matrix and reducing its stiffness.

Reinhart-King's team discovered that tumor cells were less likely to spread when their stiff ECMs were replaced with ECMs softened by irradiation. Cells suspended in a stiff matrix were more likely to work their way through the matrix to other side of a serum gradient, analogous to how metastasizing cancer cells break free from their tumors. Softened matrices were more likely to hold cells in place.

Reinhart-King said their findings might enable future fractionated radiation -- longer term bouts of therapy using a lower intensity of radiation than most of today's therapies. One particular area of interest is determining if softening can reduce nearby blood vessel leaking and improve drug delivery.

"Since there are risks associated with radiation, we're interested in investigating how fractionated the dose should be," Reinhart-King said. "The key will be to find the right balance."​​

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Fluent BioSciences awarded NIH SBIR grant to commercialize low-cost million-cell transcriptome profiling kits